D upuytren's disease is a benign fibro matosis of the hands and fingers, giving rise to the formation of nodules and cords and often leading to flexion contractures ( Fig. 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). The prev alence of Dupuytren's disease is reported to be between 0.2% and 56.0%. 1 Men are more often affected than women, but by the ninth decade of life, the incidence in women is the same as that in men. 2, 3 Standard treatment consists of surgical excision or transection of pathologic nodules and cords, but other methods of treatment are emerging. 4, 5 There is no cure for the disease, however, and reported recurrence rates range from 8% to 66%, depending on the treatment. 6, 7 The pathogenesis of Dupuytren's disease is not fully understood.
The clustering of cases of Dupuytren's disease in families suggests a genetic influence on the onset of disease; however, it is probably a complex condition in which several genetic and environmental risk factors are involved, each contributing in small part to susceptibility to the disease. To date, a limited number of small candidate-gene association studies have been performed, 8, 9 but no causal genes have been identified. To identify common genetic variants associated with this disease, we carried out a genomewide association study involving 960 persons with Dupuytren's disease and 3117 controls, all from the Netherlands and of European descent.
Me thods

Study Participants
Participants provided written informed consent, and we obtained approval from an institutional review board to carry out the study. Between 2007 and 2010, we recruited 960 patients with Dupuytren's disease through the outpatient clinics of the plastic surgery departments of six hospitals in the Netherlands. All 3117 controls for the discovery set were drawn from LifeLines, a large, populationbased cohort study being conducted in the northern Netherlands. 10 We obtained blood samples for replication studies from 189 Dutch patients with Dupuytren's disease, as well as from 561 Dutch controls who were newly enrolled in LifeLines and for whom genotyping data were already available; from 711 British patients with Dupuytren's disease, as well as from 5984 controls from the Wellcome Trust Case Control Consortium 2 (WTCCC, 1958 British Birth Cohort, and U.K. National Blood Service) for whom genotyping data were already available 11 ; and from 465 German patients with Dupuytren's disease, as well as from 1900 controls, for 1618 of whom genotyping data were already available (1164 from the PopGen study at the University of Kiel and 454 from KORA [Cooperative Health Research in the Region of Augsburg] at the Helmholtz Center Munich in Neuherberg) ( Table 1) . (A detailed description of case patients and controls is provided in the Supplementary Appendix.) Participants reported ancestry by means of a multiple-choice questionnaire, the choices being Dutch, European (specifying country), and other (specifying country). DNA samples were obtained from either blood samples (in the Dutch and German case series) or saliva (in the U.K. case series).
Tests for Association
We genotyped the Dutch samples (discovery set) and control samples (LifeLines) with Illumina HumanCytoSNP-12 arrays, comprising 301,232 SNPs, and called SNPs with the use of the Illumina algorithm (Genome Studio, version 2.10.1). To test for replication of association, we selected SNPs that showed an association in the discovery set with a P value of less than 10 −4 . We confirmed the integrity of these associations by manually inspecting genotype clusters and selected two SNPs to represent each independent locus (see the Supplementary Appendix). We genotyped the SNPs selected for tests of replication in the Dutch and British persons by means of KASP by Design assays (KBioscience). We used Human SNP Array 6.0 (Affymetrix) to genotype these SNPs in the German persons. To test for replication of SNPs for which no direct or tag SNPs were present on the Affy metrix 6.0 platform, we genotyped the selected SNPs in both the German persons affected with Dupuytren's disease and a separate control series, using GenomeLab SNPstream (Beckman Coulter).
Statistical Analysis
We excluded from the analysis specific SNPs and data from specific samples, as described previously. 12, 13 SNPs with call rates of less than 95%, a minor-allele frequency of less than 0.01, or deviation from Hardy-Weinberg equilibrium (P<0.0001) were excluded, as were samples with call rates below 99% or with a discrepancy between recorded sex and genotype-inferred sex. We also excluded relatives and ethnic outliers (see the Supplementary Appendix). Because genomewide association studies are performed in patients and controls in the same ethnic group, we used multidimensional scaling in the study participants and persons in HapMap to identify nonwhites in our study population (i.e., ethnic outliers). We compared genotype prevalence in cases and controls with the use of a basic chi-square allelic test with 1 degree of freedom and calculated the overdispersion factor of association test statistics (genomic control inflation factor, λ gc ) with the use of observed versus expected values for all SNPs by means of the PLINK software package (version 1.07). Principalcomponent analysis was performed with the use of EIGENSTRAT software to control for population stratification. We conducted conditional analysis with the use of SNPTEST, version 2, when more than one SNP with a significant genomewide association clustered at a certain region.
We excluded SNPs from tests of replication if they had a call rate below 98% or deviated from Hardy-Weinberg equilibrium (P<0.0001), and we excluded samples with call rates below 95%. We carried out a joint analysis of the discovery and replication phases with the use of Cochran-Mantel-Haenszel stratification. In the U.K. control series, not all SNPs selected for replication were available on the Illumina 1.2M and Affymetrix 6.0 genotyping platforms, which were used by WTCCC; in some cases, we used tag SNPs, and for four replication SNPs, we used imputed WTCCC control data ( Table 1 in the Supplementary Appendix) generated with BEAGLE Genetic Analysis Software Package 3.2 and based on the HapMap phase 2 reference of Centre d'Etude du Polymorphisme Humain (CEPH) persons of European ancestry (CEU). In the German series, several SNPs selected for replication were not available on the Affymetrix 6.0 platform; in these cases, tag SNPs were used as well ( Table 1 in the Supplementary Appendix). We used multiple genotyping platforms for the control cohorts in the replication phase. Since the replication signals were in the same direction and of the same magnitude as the discovery results, it is unlikely that the confirmatory results were due to biased genotyping. We checked for interplatform reproducibility by comparing genotypes of the same samples between different platforms and found concordance rates of more than 99.99% (see the Supplementary Appendix).
We were not able to correct for population stratification in the samples used to test for replication because we genotyped only a limited number of SNPs in this phase. Meta-analysis of the discovery and replication data was also performed with PLINK software. We performed an analysis with the use of the Gene Relationships across Implicated Loci (GRAIL) statistical strategy involving hg18 and PubMed data sets (December 2006), with the 11 SNPs that had a significant genomewide association as query regions. 14 
R e sult s
Genomewide Associations
Data obtained through genomewide genotyping of affected persons and controls are stored at the European Genome-Phenome Archive (accession number, EGAS00000000043). We excluded 66,293 SNP genotypes because they did not meet quality-control criteria, leaving 234,939 SNPs typed in 856 patients with Dupuytren's disease and in 2836 controls ( Table 1 ). The call rate for the remaining SNPs was 99.9%. There was moderate evidence for inflation in the test statistic (λ gc = 1.21). Adjustment for differential population stratification with the use of the first five components on the basis of a principal-component analysis of uncorrelated SNPs reduced the inflation to λ gc = 1.19. Figure 2 in the Supplementary Appendix shows that the case and control groups were well matched for population stratification after correction for these components. We found that the inflation was caused by genetic heterogeneity between persons in the north and south in the Netherlands and noted differences in case patients between the clinics ( Fig. 3 in the Supplementary Appendix). After exclusion of case patients from the most southern and eastern hospitals in the Netherlands, the inflation decreased to 1.07 ( Fig. 4 and 5 in the Supplementary Appendix). There were no signs of differences in SNP call rates between case patients and controls. After correction for the inflation factor, the quantile-quantile plots of the logarithms of our genomewide P values showed 83 data points that were above the expected diagonal line (Fig. 1A) .
In the genomewide association study, we identified eight SNPs at three loci that showed significant association (P<5×10 −8 ) ( Fig. 1B) . On chromosome 7, we identified a locus with four significantly associated SNPs. Association was strongest at rs16879765, which lies within the gene encoding ependymin-related protein 1 (EPDR1) (P = 1.9×10 −16 ; odds ratio, 1.94). The three other associated SNPs were in linkage disequilibrium with the top SNP: rs1668357 (r 2 = 0.57), rs1668347 (r 2 = 0.59), and rs952368 (r 2 = 0.44). Similarly, three significantly associated SNPs were identified at a single locus on chromosome 22. The most significant SNP on 22q, rs6519955 (P = 2.8×10 −13 ; odds ratio, 1.56), is located between wingless-type mammary-tumor virus integration site family member 7B (WNT7B) and LOC100271722, a hypothetical noncoding RNA gene. The two other associated SNPs on chromosome 22 were in linkage disequilibrium with the top SNP: rs8140558 (r 2 = 0.96) and rs4072455 (r 2 = 0.75). A conditional analysis to adjust for the top SNPs for these two loci showed no independent signals, suggesting that there is one pivotal genetic variation that drives the association of the neighboring SNPs. One additional putative Dupuy tren's disease-associated locus was identified on chromosome 19, with a single significant SNP (rs11672517) (P = 2.8×10 −8 ; odds ratio, 1.46).
Tests of Replication
To test for replication of our initial findings, we selected 35 SNPs from 24 independent loci that met the significance threshold of P<1×10 −4 in the discovery phase. We collected genotype data for the 35 SNPs in three different populations of case patients and controls, from the Netherlands, the United Kingdom, and Germany (1365 case patients with Dupuytren's disease and 8445 controls before quality control). One SNP (rs10809642) failed on genotyping in the Dutch and U.K. replication series and four SNPs (rs1123148, rs2179367, rs638791, and rs12372139) failed genotyping because of a laboratory error in the German series. One SNP (rs1668357) was out of Hardy-Weinberg equilibrium (P<0.0001) in all three replication series and was therefore excluded from further analysis. Eleven SNPs from nine different regions showed clear evidence of replication after correction for the 35 tested SNPs (P<0.0014 and association with the same allele and in the same direction as in the discovery phase) and reached genomewide significance in a meta-analysis (P<5.0×10 −8 ) ( Table 2 , and the Supplementary Appendix). All loci that showed significant associations in the discovery set also showed significant associations in the replication set: rs16879765 (P = 5.6×10 −39 ; odds ratio, 1.98) on 7p14.1, rs6519955 (P = 3.2×10 −33 ; odds ratio, 1.54) and rs8140558 (P = 1.2×10 −22 ; odds ratio, 1.39) on 22q13, and rs11672517 (P = 6.8×10 −14 ; odds ratio, 1.28) on 1p36.23-p35.1. For 2 of the 11 SNPs with a significant genomewide association, we used tag SNPs with less than complete linkage disequilibrium or imputed SNPs in the meta-analysis ( Table 1 in the Supplementary Appendix). We genotyped one of these SNPs, rs611744, on the Immunochip platform in 8274 U.K. controls (Table 1 ) and observed an association (P = 1.8×10 −14 ) on meta-analysis. The other SNP, rs8140558, is one of two SNPs at the WNT7B locus. In addition, a meta-analysis for this SNP that excluded the data from the U.K. and German series (since these data were only indirectly genotyped [ Table 1 in the Supplementary Appendix]) showed a significant genomewide association (P = 4.8×10 −16 ) ( Table 3 in the Supplementary Appendix).
Regional plots of the nine Dupuytren's disease risk loci are shown in Figure 6 in the Supplementary Appendix. To gain insight into the biologic mechanisms and to find genes functionally relat-ed at these regions, we applied GRAIL analysis. The 11 SNPs at the nine regions that had a sig nifi cant genomewide association were used as query regions, resulting in the analysis of 22 unique genes. We found a total of seven associations with SNPs (P<0.05), including four SNPs implicating four WNT genes (P<0.0001 for each) ( Table 4 in the Supplementary Appendix). When these results were corrected for multiple testing (22 tests), the associations with SNPs implicating the four WNT genes (rs7524102-WNT4, rs4730775-WNT2, rs6519955-WNT7B, and rs611744-RSPO2) remained significant (P<0.003). We observed no association between the identified SNPs with a significant genomewide association and gene expression in six quantitative-trait-locus data sets (see the Supplementary Appendix).
Discussion
We identified nine chromosomal loci associated with susceptibility to Dupuytren's disease. Very little is known about the heritability of this disease, since there are only a few reports from family and twin studies. 1517 Our findings suggest that common genetic variants have an important causative role in Dupuytren's disease in Northern European populations.
A GRAIL analysis showed that four different Dupuytren's disease risk loci contain genes that for P gwas and P meta or P<0.0014 for P replication ) are shown in bold type.
encode proteins in the Wnt-signaling pathway: 1p36.23-p35.1, containing WNT4 (rs7524102); 7q31.2, containing WNT2 (rs4730775); 22q13, containing WNT7B (rs6519955); and 8q23.1, containing RSPO2 (rs611744). Three other associated loci also contain WNT genes, although they were not implicated on GRAIL analysis: 7p14.1, containing SFRP4 (rs16879765); 8q13, containing SULF1 (rs2912522); and 6q25.1, containing TAB2 (rs2179367). However, the last of these three did not reach genomewide significance (P meta = 2.5×10 −7 ). The WNT gene family consists of structurally related genes that encode glycoproteins, extracellular signaling molecules. Abnormal Wnt signaling is linked to a range of diseases, especially cancer. The best-understood Wnt-signaling pathway is the canonical pathway, which activates the nuclear functions of β-catenin, leading to changes in gene expression that influence cell proliferation and survival. 18 Abnormal proliferation of fibroblasts is a key feature in the early development of Dupuytren's disease. The disease can be divided into three histologic stages: stage 1, proliferation of fibroblasts; stage 2, differentiation of fibroblasts into myofibroblasts; and stage 3, formation of mature type 1 collagen. 19, 20 Wnt signaling is known to regulate the proliferation and differentiation of fibroblasts in both cancer and fibromatosis. 21 Most of our knowledge of Wnt signaling is derived from studies of cancer. In colon cancer, up-regulation of Wnt signaling causes intestinal crypt cells to proliferate for longer than usual before they migrate and differentiate. 22 This prolonged proliferation phase results in the formation of polyps and confers a predisposition to cancer.
The involvement of the Wnt-signaling pathway in the pathogenesis of Dupuytren's disease is consistent with features of the disease and with established aspects of Wnt signaling. An imbalance of Wnt signaling in Dupuytren's disease could cause fibroblasts in the fascia of the hand to proliferate and form nodules. Indeed, increased levels of β-catenin have been observed in primary cell cultures in vitro, 23 suggesting that the Wnt-signaling pathway is overstimulated in Dupuytren's disease.
The Wnt proteins Wnt2, Wnt4, and Wnt7B, which were identified on GRAIL analysis, bind to frizzled receptors, leading to a cascade of events that eventually result in a decrease in the rate of β-catenin degradation 18 (Fig. 2) . Secreted frizzled-related proteins, such as SFRP4, antagonize the Wnt-signaling pathway by binding to either Wnts or frizzled receptors, thereby affecting receptor occupancy. In the absence of active Wnt, β-catenin is degraded, and potential target genes will not be activated.
Another Dupuytren's disease risk locus contains RSPO2, encoding an R-spondin; members of the R-spondin family interact with frizzled receptors and LRP5/6 to induce β-catenin signaling. Furthermore, R-spondins induce canonical Wnt signaling by competing with the dickkopf (DKK) protein for binding to LRP5/6. The DKK protein is an inhibitor of Wnt signaling; it hinders the formation of a complex among Wnt, frizzled receptor, and LRP5/6 (Fig. 2) . 25 SULF1, a heparan sulfate 6-O-endosulfatase, is known to influence canonical Wnt signaling. How it does so is not clear, but 6-O-desulfation of heparan sulfate proteoglycans may alter the binding of Wnt to its frizzled receptor. 26, 27 Increased activity of these WNT and R-spondin genes or decreased activity of SFRP could stimulate Wnt signaling and reduce intracellular β-catenin degradation. This mechanism could trigger fibroblasts to proliferate, leading to the development of Dupuytren's disease.
Also supporting a role for Wnt signaling in Dupuytren's disease is the microRNA (miRNA) expression profiles of fibroblasts and palmar fascia in persons with this disease, as compared with those in healthy controls. These miRNAs regulate genes related to the β-catenin pathway: WNT5A, ZIC1, and TGFB1. 28 The three remaining significant loci lack an obvious connection to the Wnt pathway. An interesting candidate gene from these regions is MAFB. The RNA of MAFB has been shown to be up-regulated in the excised cord tissue from persons with Dupuytren's disease, as compared with fascia of the hand in healthy controls. 29 Maf proteins are known for their role in fibrosarcoma and are believed to influence tissue development and cellular differentiation. 30 MAFB can transform primary fibroblasts in vitro. 31 The gene might therefore be involved in stage 2 of Dupuytren's disease (the differentiation of fibroblasts into myofibroblasts). The miRNA expression profile associated with Dupuytren's disease implicated some miRNAs in influencing the expression of MAFB as well. 28 The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF GRONINGEN on July 3, 2012. For personal use only. No other uses without permission.
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The results of our study indicate that genetic factors have a major role in the development of Dupuytren's disease. Associations with variations in genes that encode proteins in the Wnt-signaling pathway suggest that aberrations in this pathway confer susceptibility to the disease. Further genetic and basic research is required to fully unravel the pathogenesis of Dupuytren's disease. The nine susceptibility regions in Dupuytren's disease include three WNT genes, one gene for secreted frizzledrelated protein (SFRP), and one gene for R-spondin (RSPO2). Panel A shows that in the absence of Wnt protein, β-catenin (β-cat) is degraded, and forthcoming target genes are in a repressed state. Panel B shows that if Wnt signaling is active, β-catenin degradation is reduced. SFRPs antagonize the Wnt-signaling pathway by binding to either Wnt or frizzled receptor, thereby affecting receptor occupancy. R-spondin positively regulates β-catenin signaling by interacting with the frizzled receptor and the low-density lipoprotein-receptor-related protein (LRP5/6) and by competing with the dickkopf protein (DKK). 18, 24 APC denotes adenomatous polyposis coli, CBP cyclic AMP response-elementbinding (CREB) protein-binding protein, CK1 casein kinase 1, DSH disheveled protein, GBP GSK3-binding protein, GSK3 glycogen synthase kinase 3, P phosphorylation, SFRP secreted frizzled-related protein, and TCF T-cell factor. 
